Vistusertib, also known as AZD2014, is a small molecule inhibitor of the mammalian target of rapamycin (mTOR) kinase. It is currently being studied for its potential therapeutic use in various types of cancer.
Chemical name: (2S)-1-N-[(1S)-3-amino-1-[7-fluoro-1-(1-methylethyl)-1H-indol-5-yl]propan-2-yl]-2-hydroxypropyl-2-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxamide Molecular formula: C28H32FN5O2 Formula weight: 475.59 g/mol CAS No: 1009298-59-2
Top ten keywords from Google and Synonyms:
Health benefits of this product: Vistusertib has shown promising results in preclinical and clinical studies for its potential use in treating various types of advanced solid tumors, such as renal cell carcinoma and tuberous sclerosis. Its ability to inhibit mTOR, a key regulator of cell growth and proliferation, may lead to the suppression of tumor growth and the induction of apoptosis, or programmed cell death.
Potential effects: Studies have demonstrated that Vistusertib has potential therapeutic effects in various types of cancers. It has also been shown to have potential in treating other diseases, such as tuberous sclerosis and autism spectrum disorders.
Product mechanism: Vistusertib works by inhibiting the activity of mTOR, a key enzyme in the PI3K/AKT/mTOR signaling pathway. This pathway is critical for regulating cell growth and proliferation, and its dysregulation can lead to uncontrolled cell growth and tumor formation. By inhibiting mTOR, Vistusertib can block the downstream activation of key signaling molecules such as AKT and S6 kinase, which are essential for cell survival and growth. This leads to apoptosis, or programmed cell death, and the suppression of cancer cell growth.
Safety: As with any medication, safety is a concern when using Vistusertib. Studies have shown that it is generally well-tolerated and has a good safety profile. However, like other mTOR inhibitors, it can cause side effects such as diarrhea, nausea, vomiting, and fatigue. It is important to consult with a healthcare provider before using Vistusertib and to closely monitor any potential side effects.
Side effects: Some of the common side effects of Vistusertib include gastrointestinal symptoms such as diarrhea, nausea, vomiting, and abdominal pain. Other potential side effects include fatigue, headache, and rash. In rare cases, Vistusertib can cause serious side effects such as liver toxicity and lung inflammation, so close monitoring is recommended.
Dosing information: Vistusertib is typically administered orally as a tablet. The optimal dose and duration of treatment will vary depending on the individual patient and the type of disease being treated. It is important to follow dosing instructions carefully and to consult with a healthcare provider before beginning treatment with Vistusertib.
Conclusion: Vistusertib is a promising small molecule inhibitor that has demonstrated potential in treating various types of cancer by inhibiting the activity of mTOR, a key regulator of cell growth and proliferation. Although it has a good safety profile, potential side effects must be closely monitored. Further research is needed to fully explore the therapeutic potential of Vistusertib and its applications in treating various diseases.
